CHMG(CHMG)
CHMG
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $125M | $134M |
| Low | $125M | $134M |
| High | $125M | $134M |
| EBITDA Avg | $36M | $38M |
| Low | $36M | $38M |
| High | $36M | $38M |
| EBIT Avg | $33M | $35M |
| Low | $33M | $35M |
| High | $33M | $35M |
| Net Income Avg | $36M | $38M |
| Low | $36M | $38M |
| High | $36M | $38M |
| EPS Avg | $7.57 | $7.95 |
| Low | $7.57 | $7.95 |
| High | $7.57 | $7.95 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $32M | $32M | $32M | $33M | $34M | $35M |
| Low | $32M | $32M | $32M | $33M | $34M | $35M |
| High | $32M | $32M | $32M | $33M | $34M | $35M |
| EBITDA Avg | $9M | $9M | $9M | $9M | $10M | $10M |
| Low | $9M | $9M | $9M | $9M | $10M | $10M |
| High | $9M | $9M | $9M | $9M | $10M | $10M |
| EBIT Avg | $8M | $8M | $8M | $9M | $9M | $9M |
| Low | $8M | $8M | $8M | $9M | $9M | $9M |
| High | $8M | $8M | $8M | $9M | $9M | $9M |
| Net Income Avg | $9M | $9M | $9M | $10M | $10M | $10M |
| Low | $9M | $9M | $9M | $10M | $10M | $10M |
| High | $9M | $9M | $9M | $10M | $10M | $10M |
| EPS Avg | $1.91 | $1.91 | $1.92 | $1.97 | $2.02 | $2.04 |
| Low | $1.91 | $1.91 | $1.92 | $1.97 | $2.02 | $2.04 |
| High | $1.91 | $1.91 | $1.92 | $1.97 | $2.02 | $2.04 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |